ProPhase Labs Restates Q1 2026 Financials: Revenue Nearly Triples, Loss Narrows
PRPH is trading near its 52-week low of $0.068 (12% above the low) on light trading volume (0.1× avg).
Summary
ProPhase Labs restated its Q1 2026 results, nearly tripling revenue to $1.17M and narrowing its net loss to $5.18M. The company remains in critical condition with minimal cash and a going concern warning.
Key Events · Earnings and Guidance · PRPH
-
Q1 2026 Financials Restated
Revenue restated to $1.169M from $478K; net loss improved to $5.175M from $5.354M; EPS improved to ($0.42) from ($0.43).
-
Restatement Details
Errors in revenue, cost of goods sold, and deferred revenue corrected. Gross margin now 25.3% vs. previously reported 34.9%.
-
Going Concern Warning Reiterated
Cash of $31K, working capital deficit of $52.8M, and management's plans do not alleviate substantial doubt about the company's ability to continue as a going concern.
-
Auditor Non-Review Confirmed
Amendment No. 2 confirms the original 10-Q was not reviewed by the company's independent registered public accounting firm, as first disclosed in Amendment No. 1.
Analysis · PRPH · Life Sciences
ProPhase Labs filed Amendment No. 2 to its Q1 2026 10-Q, restating previously reported financials. The restatement nearly triples revenue to $1.17 million from the originally reported $478,000, and narrows the net loss to $5.18 million from $5.35 million. While the restated figures are an improvement, the company remains in severe distress with just $31,000 in cash, a going concern warning, and a massive working capital deficit. The amendment also confirms the original 10-Q was not reviewed by the company's independent auditor, a governance red flag. This restatement, while correcting errors, does not change the fundamental picture of a company fighting for survival.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRPH was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $722.4K. The 52-week trading range was $0.07 to $66.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.